Delving into the Latest Updates on Taxolog, Inc. with Synapse

概览

关联

5

项与 Taxolog, Inc. 相关的药物

TL-1892

靶点-

作用机制-

在研机构-

原研机构

Taxolog, Inc.

在研适应症-

非在研适应症

肿瘤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

Simotaxel

靶点

Tubulin

作用机制

微管蛋白抑制剂

在研机构-

原研机构

University of Florida

在研适应症-

非在研适应症

晚期恶性实体瘤 [+2]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

TL-1836

靶点-

作用机制-

在研机构-

原研机构

Taxolog, Inc.

在研适应症-

非在研适应症

肿瘤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

2

项与 Taxolog, Inc. 相关的临床试验

EUCTR2007-002083-98-HU

/ Not yet recruitingN/A

A Phase II Study of Milataxel (TL139) Administered Orally or Intravenously in Taxane Naïve Patients with Metastatic Breast Cancer.

开始日期2008-08-19

申办/合作机构

Taxolog, Inc.

NCT00685204

/ Unknown status临床2期

A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma

Milataxel is a new taxane that may have several advantages over the currently available taxanes. The current study is designed to determine the response rate of oral Milataxel in patients with malignant Mesothelioma. The study specifically targets patients who have recurring or progressive disease following previous chemotherapy.

开始日期2008-03-01

申办/合作机构

Taxolog, Inc.

100 项与 Taxolog, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Taxolog, Inc. 相关的专利（医药）

登录后查看更多信息

5

项与 Taxolog, Inc. 相关的文献（医药）

2009-06-01·Anti-Cancer Agents in Medicinal Chemistry4区 · 医学

Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?

4区 · 医学

Review

作者: Monteiro, Alvaro N. A. ; DeLigio, J. Thomas ; Velkova, Aneliya ; Zorio, Diego A. R.

Taxanes (paclitaxel and docetaxel) are currently used to treat ovarian, breast, lung, and head and neck cancers. Despite its clinical success taxane-based treatment could be significantly improved by identifying those patients whose tumors are more likely to present a clinical response. In this mini-review we discuss the accumulating evidence indicating that the breast and ovarian cancer susceptibility gene product BRCA1 mediates cellular response to taxanes. We review data from in vitro, animal, and clinical studies, and discuss them in context of response to therapy. We argue that levels of BRCA1 in tumors may provide a predictive marker for the response to treatment with taxanes. In addition, the study of the role of BRCA1 in the mechanism of action of taxanes might reveal alternative approaches to avoid resistance.

2009-04-01·Journal of Pharmaceutical and Biomedical Analysis3区 · 医学

Overcoming extractability hurdles of a 14C labeled taxane analogue milataxel and its metabolite from xenograft mouse tumor and brain tissues

3区 · 医学

Article

作者: Safarpour, Hudan ; Wilcox, Everett ; Connolly, Paul ; Bielawski, Mike ; Tong, Xiaojie

Taxane analogue milataxel have been shown to bound to proteins/tissues irreversibly. Extraction of the aforementioned bound drug and metabolite was proven to be difficult task. Nonetheless, an extraction method had to be developed to accurately determine drug concentration in tissues over time. This method would enable Taxolog, Inc. (Fairfield, NJ, USA) to accurately map the fate of drug in mice and it would also enable to better design drug dosing scheme for its maximum efficiency. A productive extraction technique for milataxel (MAC-321, TL-139) in nude mice with various xenograft human tumors was developed by extracting analytes from tumors using a novel extraction procedure and analyzing samples by LC-MS. This extraction technique entails disrupting tissue cells with hexane followed by acidic methanol (MeOH), with the aid of a tissuemizer and sonic cell disrupter. An average extractability of 75% was achieved as confirmed by the recovery of 14C labeled milataxel, as compared to 4-48.5% extraction efficiency using solvents and/or combination of solvents such as acetonitrile (ACN), ethanol, ethyl acetate, MeOH/acetic acid in water, and chloroform/MeOH. This extraction technique allowed for quantitation of milataxel and its major metabolite s-lactate (M-10) from tumors and brain tissue samples using HPLC coupled with electro-spray ionization mass spectrometry (HPLC-ESI-MS). Ratios of M-10 metabolite to milataxel were determined to be approximately 3:1 and 2:1 in SKMES human lung carcinoma tumors and A-375 melanoma tumors, respectively, and declined in concentration over 20 days. However, levels of milataxel and M-10 were determined to be equal at 8h in HCT-15 human colon carcinoma tumors with M-10 levels dropping sharply over a 10-day period.

2008-07-01·Lab Animal1区 · 农林科学

Response to Protocol Review Scenario: More references required

1区 · 农林科学

Article

作者: Arrington, Heather A

100 项与 Taxolog, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Taxolog, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年02月02日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

5

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

TL-1836	肿瘤更多	终止
TL-1892	肿瘤更多	终止
Milataxel ( Tubulin )	恶性间皮瘤更多	无进展
TL-310 ( Tubulin )	肿瘤更多	无进展
Simotaxel ( Tubulin )	实体瘤更多	无进展